Drugs / Symbicort pMDI
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT00536731 Comparator | Sep 2007 → Apr 2008 | asthma | AstraZeneca | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Symbicort pMDI | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00536731 ↗ |
| Route | Inhaled | “Symbicort®pMDI® 40/2.25 μg 2 Actuations Twice Daily” NCT00536731 ↗ |